Skip to content

Intra-subject variability in pain scoring and the consequences for analgesia treatment

Intra-subject variability in pain scoring and the consequences for analgesia treatment - The VAPAANA Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON44114
Enrollment
180
Registered
2013-01-15
Start date
2013-01-18
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obesitas Chronic and acute pain fibromyalgia obesity polyneuropathy

Interventions

Alfentanil. Alfentanil is a µ-opioid receptor agonist used for the treatment of acute pain. Using the TCI system alfentanil concentrations will be set at 100 ng/ml, 200 ng/ml in 2 groups of 10 subje

Sponsors

Leids Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Healthy subjects of either sex between the age of 18 and 75; ;Patient inclusion criteria: (i) Patients diagnosed with fibromyalgia or peripheral polyneuropathy according to the guidelines of the IASP or other professional pain societies (eg., Netherlands Society of Anesthesiologists); or patients scheduled for elective surgery with post-operative opiate treatment; (ii) a pain score of 5 or higher for chronic pain patients; (iii) age between 18 and 75 years; Obesity patients: BMI > 35

Exclusion criteria

Exclusion criteria: Medical disease such as pulmonary, renal, liver, cardiac, gastro-intestinal, vascular disease; allergy to study medication; use of strong opioids; use of benzodiazepines; raised intracranial pressure;(x) pregnancy and/or lactation

Design outcomes

Primary

MeasureTime frame
Heat and electrical pain VAS scores

Secondary

MeasureTime frame
Questionnaires for obese patients QST values corneal confocal microscopy results conditioned pain modulation offset analgesia temporal summation

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)